An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
The companies will supply doses to Singapore through 2021 following emergency use authorization from U.S. Food and Drug Administration and interim authorization for pandemic supply from Singapore Health Sciences Authority
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines